## MLM: Martin Marietta Materials, Inc. - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_20 -1.8% below STRENGTH zone (4.0-10.0%); PEG 3.58 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (59% of avg), momentum weakening (-3.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($582.71)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. MLM: Morgan Stanley Raises Price Target to $660, Maintains Overw**
- Source: GuruFocus | 20251201T123100 | Somewhat-Bullish | Relevance: 99%
- Morgan Stanley has raised its price target for Martin Marietta Materials (MLM) to $660 from $610, while maintaining an Overweight rating, reflecting continued confidence in the company's market position and growth prospects. This adjustment represents an 8.20% increase in the price target. Other analysts have also recently updated their ratings and price targets for MLM, including JP Morgan, Stifel, UBS, Wells Fargo, and Raymond James.

**2. Choreo LLC Boosts Holdings in Martin Marietta Materials, Inc. $MLM**
- Source: MarketBeat | 20251130T093650 | Neutral | Relevance: 98%
- Choreo LLC significantly increased its stake in Martin Marietta Materials (NYSE:MLM) by 77.2% in Q2, bringing its total to 3,103 shares valued at $1.70 million. Despite institutional investors owning 95.04% of the stock, Martin Marietta missed quarterly earnings and revenue expectations. Analysts maintain a "Moderate Buy" consensus with an average price target of $644.38.

**3. Elevation Point Wealth Partners LLC Invests $463,000 in Martin Marietta Materials, Inc. $MLM**
- Source: MarketBeat | 20251130T100624 | Somewhat-Bullish | Relevance: 98%
- Elevation Point Wealth Partners LLC initiated a new position in Martin Marietta Materials (NYSE:MLM) by purchasing 843 shares valued at approximately $463,000 during the second quarter. Other institutional investors also adjusted their holdings in MLM. The company currently has a "Moderate Buy" rating from analysts with an average target price of $644.38, despite missing quarterly EPS estimates and announcing a dividend of $0.83 per share.

**4. Martin Marietta Materials, Inc. $MLM is M.D. Sass LLC's 7th Largest Position**
- Source: MarketBeat | 20251202T130357 | Neutral | Relevance: 98%
- M.D. Sass LLC slightly reduced its stake in Martin Marietta Materials, Inc. (NYSE:MLM) by 1.1% in Q2 2025, yet the stock remains its 7th largest position, valued at approximately $67.5 million. The company missed Q3 2025 earnings expectations with an EPS of $5.97 versus $6.62 expected and revenue of $1.85 billion against $2.06 billion. Despite this, analysts maintain a "Moderate Buy" consensus rating with an average target price of $644.38, and the company announced a quarterly dividend of $0.83 per share.

**5. How Investors Are Reacting To Martin Marietta Materials (MLM) Shift Toward High-Margin Aggregates Business**
- Source: Simply Wall Street | 20251202T233752 | Somewhat-Bullish | Relevance: 98%
- Martin Marietta Materials is shifting its focus to its high-margin aggregates business through an asset exchange with Quikrete Holdings Inc., aiming to improve its operating portfolio and financial outlook. This move is supported by record profitability in aggregates and increased full-year 2025 Adjusted EBITDA guidance, anticipating continued benefits from infrastructure investments and strong construction market demand. The article explores how this strategic shift might influence Martin Marietta's investment prospects amidst potential policy uncertainties regarding public infrastructure funding.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-01 | Morgan Stanley | $660 | $610 | +8% |
| 2025-11-11 | Stifel | $681 | $637 | +7% |
| 2025-11-11 | JP Morgan | $700 | $670 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-01 | Morgan Stanley | main | Overweight |
| 2025-11-11 | Stifel | main | Buy |
| 2025-11-11 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.12M) |
| Sells | 3 ($0.33M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.3% (+1.3%)
- JPMORGAN CHASE & CO: 9.7% (+98.6%)
- Blackrock Inc.: 6.9% (-1.8%)
- FMR, LLC: 4.8% (-4.3%)
- State Street Corpora: 4.6% (-1.0%)

### Key Risks

1. Valuation stretched: PEG 3.6x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +7%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 3.58 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 17%). Balance sheet: strong liquidity (3.0x). Analyst sentiment positive (3 raises, avg +7%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $37.6B |
| Beta | 1.16 |
| 52W Range | $441.95 - $665.18 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.58 |
| Forward P/E | 27.5 |
| Current P/E | 32.6 |
| YoY Growth | 18.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.9% to -1.8% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.8pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.08x) but short-term weakness (below SMA20). MACD histogram positive (1.90), confirming momentum. RSI neutral at 47. Volume at 59% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.84% (CS: 36) | Neutral |
| RSI_14 | 47.1 | Neutral |
| MACD Histogram | 1.90 | Bullish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 0.983x | Below |
| vs SMA200 | 1.079x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $607.99
- **Stop Loss:** $582.71 (4.2% risk)
- **Target:** $633.27 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 39
- **Position Value:** $23,711.61
- **Portfolio %:** 23.71%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-11 (Est: $4.98)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.68 | $6.85 | +2.5% |
| 2025Q2 | $5.26 | $5.43 | +3.2% |
| 2025Q1 | $1.88 | $1.90 | +1.1% |
| 2024Q4 | $4.56 | $4.81 | +5.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*